Celgene discovers, develops and commercializes innovative therapies to treat cancer and immune-inflammatory-related diseases.
Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 21, 2017
Rapt Therapeutics
|
Series C | $60M | Biotechnology | — |
Nov 13, 2017
Arcus Biosciences
|
Series C | $107M | Biotechnology | — |
Jul 11, 2017
Evelo Biosciences
|
Series B | $50M | Biotechnology | — |
Sep 1, 2016
Arcus Biosciences
|
Series B | $70M | Biotechnology | — |
May 24, 2016
COTA Healthcare
|
Series B | — | Artificial Intelligence | — |